Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its 4 % QRX003 lotion for the treatment of Netherton Syndrome, a rare genetic skin disorder with no approved therapies.
Fast Track status enables more frequent FDA interactions and the possibility of accelerated review pathways, potentially shortening the time to regulatory approval and market entry for QRX003. The designation follows prior orphan drug and pediatric rare disease approvals: the FDA granted orphan drug designation on October 21, 2025; the European Medicines Agency granted orphan drug designation in May 2025 (or June 20, 2025, depending on the source); and the FDA also granted a pediatric rare disease designation earlier in the year.
QRX003 is a topical lotion formulated with a broad‑spectrum serine protease inhibitor that mimics the function of the missing LEKTI protein in Netherton Syndrome patients. It is currently being evaluated in two late‑stage whole‑body clinical trials, with enrollment expected to be completed in Q1 2026 and top‑line data anticipated in the second half of 2026. The trials aim to assess safety, efficacy, and improvements in skin barrier function, itch reduction, and patient quality of life.
Orphan drug designation provides potential market exclusivity upon approval, while the Fast Track designation may facilitate a faster regulatory pathway and offer data protection. Together, these designations position QRX003 as a first‑in‑class treatment for a disease with no approved therapies, potentially opening a significant unmet medical need market.
"We believe that the FDA's decision to grant Fast Track Designation to QRX003 reflects the urgent unmet need faced by patients and families living with Netherton Syndrome," said Dr. Michael Myers, CEO and Co‑Founder of Quoin Pharmaceuticals. "Fast Track status enables more frequent communication with the FDA and the potential for accelerated regulatory review pathways, which may help bring the first approved treatment for Netherton Syndrome to patients as quickly as possible." He added, "Receiving Orphan Drug Designation from the FDA is yet another important milestone in our mission to bring QRX003 to patients suffering with Netherton Syndrome. Together with the EMA designation granted earlier in the year, this latest recognition by the FDA could potentially help facilitate the pathway of QRX003 to approval in the US whilst providing significant data protection to the product, if approved. Quoin remains steadfastly committed to completing the clinical development of QRX003 with a high degree of urgency on behalf of patients and families living with this devastating disease."
The Fast Track designation, combined with orphan and pediatric rare disease approvals, signals a clear regulatory momentum for QRX003. It underscores Quoin’s focus on rare and orphan diseases and may accelerate the drug’s path to market, potentially providing the first approved therapy for Netherton Syndrome and creating a new revenue stream for the company once the product is approved.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.